Financial Data and Key Metrics Changes - For Q4 2024, the company reported revenues of approximately $169 million, a decrease of 2% compared to Q4 2023, and adjusted EBITDA of approximately $18 million, down 18% year-over-year [21] - Full year 2024 adjusted revenues were approximately $563 million, a decrease of about 3% from 2023, with adjusted EBITDA at $42 million compared to $53 million in the prior period [22][23] - The adjusted EBITDA margin for 2024 was 7.5%, which management believes is about half of the company's full cycle earnings potential [13] Business Line Data and Key Metrics Changes - The company is focusing on improving its balance sheet, reporting a reduction in inventory by approximately $47 million during Q4, although it slightly missed its inventory to sales target [24] - Average inventory turns for 2024 ended at 1.67%, with a target of about 2 turns by year-end 2025 [24] Market Data and Key Metrics Changes - Management noted a slight improvement in sentiment among growers since the low point in summer 2024, but purchasing remains conservative due to high capital costs and tariff uncertainties [16] - The company anticipates that 2025 will be better than 2024, with adjusted EBITDA target range of $45 million to $52 million and sales expected between $565 million and $585 million [18] Company Strategy and Development Direction - The new CEO emphasized the need to improve margins, rightsize the balance sheet, and return to growth, indicating that the company has a resilient revenue base to build upon [9] - The company is undergoing a transformation plan that includes exiting certain markets, cutting costs, and implementing an ERP system to simplify operations [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism for 2025, noting that while the agricultural economy is gradually improving, farmers are still cautious due to potential tariff impacts [33] - The CEO highlighted that the company aims to generate free cash flow and strengthen its balance sheet by decreasing net working capital and paying down debt [35] Other Important Information - The company recorded $118 million in nonrecurring charges for 2024, primarily related to asset impairments and transformation projects [27] - There is a delay in filing the audited 10-K due to complex assessments related to write-downs, with plans to file a 12b-25 with the SEC [29] Q&A Session Summary Question: Timing of the financial filing - Management indicated that the filing would occur within weeks, not months, and attributed the delay to complex write-downs rather than any surprising issues [40][41] Question: Working capital expectations for 2025 - Management stated that inventory is the primary focus for reducing working capital, with a refreshed SIOP model to enhance efficiency [45] Question: Addressing organizational complexity - The CEO noted that a modernized ERP system and organizational restructuring are key steps to reduce complexity and improve accountability [48] Question: Impact of tariffs on farmer buying patterns - Management confirmed that uncertainty around tariffs is causing farmers to adopt a just-in-time purchasing approach, impacting revenue guidance [52][53] Question: Margin improvement expectations - The CEO outlined that achieving mid-teens EBITDA margins will involve improving gross margins and reducing operating expenses as a percentage of sales [62] Question: Earnings cadence for 2025 - Management expects lower EBITDA margins in the first half of 2025, with improvement anticipated in the second half [66] Question: Confidence in 2025 guidance - The CEO expressed confidence in the 2025 guidance, with the lower end reflecting slower industry conditions and the upper end indicating positive growth [69][70]

Financial Data and Key Metrics Changes - For Q4 2024, the company reported revenues of approximately $169 million, a decrease of 2% compared to Q4 2023, and adjusted EBITDA of approximately $18 million, down 18% year-over-year [21] - For the full year 2024, adjusted revenues were approximately $563 million, a decrease of about 3% from 2023, with adjusted EBITDA at $42 million compared to $53 million in the prior period [22][23] Business Line Data and Key Metrics Changes - The company is focusing on improving its balance sheet, reporting inventories at approximately $180 million, which included write-downs for obsolescence and slow-moving items [22] - The average inventory turns for 2024 ended at 1.67%, with a target to push this metric towards about 2 turns by year-end 2025 [24] Market Data and Key Metrics Changes - The agricultural economy is showing signs of gradual improvement, with customers indicating a slight improvement in sentiment since the low point in summer 2024, although they remain conservative in buying patterns [16] - The company anticipates that 2025 will be better than 2024, with an adjusted EBITDA target range of $45 million to $52 million and expected sales between $565 million and $585 million [18] Company Strategy and Development Direction - The new CEO emphasized the need to improve margins, rightsize the balance sheet, and return to growth, with a focus on simplifying operations and prioritizing key tasks [9][14] - The company plans to allocate the bulk of its free cash flow towards debt repayment as part of its transformation strategy [19] Management's Comments on Operating Environment and Future Outlook - Management noted that while the agricultural economy is improving, farmers are cautious due to high capital costs and potential tariffs, leading to a just-in-time purchasing approach [16][53] - The CEO expressed confidence that 2025 will show improvement over 2024, contingent on resolving tariff issues and improving market conditions [54] Other Important Information - The company recorded $118 million in nonrecurring charges for 2024, primarily related to asset impairments and transformation projects [27] - There is a delay in filing the audited 10-K due to complex assessments related to write-downs, with plans to file a 12b-25 with the SEC [29] Q&A Session Summary Question: Timing of the financial filing - Management indicated that the filing would occur within weeks, not months, and the delay was due to complex write-down assessments rather than any surprising issues [40][41] Question: Working capital expectations for 2025 - The focus remains on inventory as the primary area for working capital improvement, with a refreshed SIOP model to enhance efficiency [45] Question: Addressing organizational complexity - The CEO discussed steps taken to simplify the organization, including an ERP system implementation and restructuring for accountability [47][48] Question: Impact of tariffs on farmer buying patterns - Management noted that uncertainty from tariffs is causing farmers to be cautious, affecting their purchasing decisions [53] Question: Confidence in 2025 guidance - The CEO expressed confidence in the guidance, with the lower end reflecting slower industry conditions and the upper end reflecting positive influences on purchasing [69] Question: Transformation costs for 2025 - Projected transformation costs for 2025 are around $5 million, significantly lower than in 2024, with expected benefits from commercial activities and logistics [72]

FY 2024 Earnings March 2025 Safe Harbor Statement During this presentation, the Company may discuss forward-looking information. Except for the historical information contained in this release, all forward-looking statements are estimates by the Company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include weather conditions, changes in regulatory policy and other risks as detailed from time-to-time in th ...

Financial Results Announcement - American Vanguard Corporation announced its unaudited financial results for the three- and twelve-month periods ended December 31, 2024[4]. - The press release detailing the financial results was issued on March 14, 2025[4]. - The financial results include both quarterly and annual performance metrics[4]. Company Information - The company is listed on the New York Stock Exchange under the symbol AVD[2]. - The report does not indicate whether the company is an emerging growth company[3]. Performance Guidance and Outlook - The company has not provided specific performance guidance or future outlook in the available documents[4]. Product and Market Development - There is no mention of new product development or technological advancements in the current report[4]. - The report does not discuss market expansion or acquisition strategies[4]. Documentation and Signatures - The financial statements and exhibits are included in the press release linked as Exhibit 99.1[6]. - The report was signed by Timothy J. Donnelly, Chief Information Officer, General Counsel & Secretary[9].

Sales Performance - Overall sales for Q3 2024 declined by 21% compared to Q3 2023, with domestic sales down 33% and international sales down 4%[66]. - Consolidated sales decreased by 6% in the first nine months of 2024 compared to the same period in 2023, with domestic sales down 9% and international sales down 2%[84]. - Total net sales declined by 21% to $118,307 from $149,516 in the prior year[71]. - U.S. crop net sales decreased by 17% to $155,075 in the first nine months of 2024, while U.S. non-crop sales increased by 18% to $59,241[87]. - International net sales decreased by 4% to $60,320, impacted by supply constraints in Asia and a weakening currency in Brazil[74]. - International net sales were down 2% to $167,343, primarily due to weak performance from the Mocap and Assure II products[90]. Profitability - Gross profit for Q3 2024 was $17,293, representing 15% of net sales, a significant decrease from 29% in the same period last year[67][75]. - Gross profit margin fell to 26% in the first nine months of 2024, down from 31% in the same period of 2023, largely due to a $16,191 liability from the Dacthal product recall[85]. - Gross profit decreased by 60% to $17,293, with a gross margin percentage of 15%, down from 29% in the previous year[75]. - The company recorded a net loss of $25,742, or $(0.91) per share, compared to a loss of $325, or $(0.01) per share, in the prior year[70]. - The company recorded a net loss of $35,911 or ($1.28) per share for the first nine months of 2024, compared to net income of $540 or $0.02 per share in the same period of 2023[87]. Operating Expenses - Operating expenses increased by 17% to $45,681, including non-recurring charges of $8,139 related to ongoing transformation activities[68][77]. - Operating expenses increased by 14% year-over-year, reaching $129,003 for the nine-month period ended September 30, 2024[93]. - Research, product development, and regulatory expenses increased by $2,097 to $11,177, reflecting higher costs associated with regulatory and product development studies[77]. Debt and Interest - The company’s average overall debt for Q3 2024 was $209,840, with an effective interest rate of 8.1%, up from 7.1% in the prior year[80]. - Interest expense rose to $4,378 from $3,384 in the same period last year, primarily due to higher interest rates[69][80]. - Interest expense increased to $11,988 for the nine months ended September 30, 2024, compared to $8,282 in the same period of 2023, reflecting higher interest rates[96]. - The company's average overall debt increased to $200,187 for the nine months ended September 30, 2024, from $149,009 in the prior year[97]. Taxation - The effective income tax rate for Q3 2024 was approximately 21.4%, with a tax benefit of $7,024 compared to an expense of $885 in the same period last year[81]. - The company achieved an income tax benefit of $7,093 for the nine months ended September 30, 2024, compared to an expense of $2,066 in the same period of 2023[98]. Cash Flow and Liquidity - Operating activities utilized net cash of $29,402 during the nine-month period ended September 30, 2024, compared to $145,854 during the same period in 2023[100]. - Customer prepayments decreased by $38,375, compared to a decrease of $104,590 in the same period of 2023[103]. - The Company anticipates that cash flow from operations, existing cash balances, and available borrowings will be sufficient to meet liquidity needs for the next twelve months[109]. Product Recall Impact - Domestic crop business net sales were 48% lower than Q3 2023, primarily due to the voluntary product recall of Dacthal, which accounted for $11,783 in lost sales[71][72]. - The company recorded a liability of $16,191 associated with the global voluntary cancellation of the Dacthal registrations[91].

Financial Performance - Net sales for Q3 2024 were $118.3 million, down from $149.5 million in Q3 2023, with an adjusted figure of $130.7 million excluding the Dacthal product recall impact[2]. - Adjusted EBITDA for Q3 2024 was $1.8 million compared to $11.4 million in Q3 2023, maintaining full-year 2024 guidance of $40 million to $50 million[2][4]. - The company reported a net loss per share of $(0.92) for Q3 2024, compared to a loss of $(0.01) in Q3 2023[2][4]. - Total net sales decreased by 21% to $118,307,000 for the three months ended September 30, 2024, compared to $149,516,000 in the same period of 2023[11]. - Total gross profit declined by 60% to $17,293,000, down from $43,084,000 year-over-year[11]. - The net loss for the nine months ended September 30, 2024, was $35,911,000, compared to a net income of $540,000 in the same period of 2023[14]. - Adjusted EBITDA for the three months ended September 30, 2024, was $1,800,000, significantly lower than $11,364,000 in the prior year[15]. - The company experienced a decrease in cash flows from operating activities, with a net cash used of $29,849,000 for the nine months ended September 30, 2024[14]. Revenue Breakdown - Non-crop revenues grew by 17% year-over-year, while green solutions revenues increased by 18% year-over-year[3]. - U.S. crop sales fell by 48% to $35,533,000, while U.S. non-crop sales increased by 17% to $22,454,000[11]. - International sales decreased by 4% to $60,320,000, compared to $62,517,000 in the same quarter of 2023[11]. - The impact of the Dacthal recall resulted in a reduction of $12,403,000 in total net sales[12]. Debt and Assets - The company reduced its long-term debt by $32.5 million, bringing it down to $178.7 million from $211.2 million in the previous quarter[2][4]. - Total assets as of September 30, 2024, were $759.5 million, down from $767.5 million at the end of 2023[9]. - Cash and cash equivalents at the end of the period were $11,880,000, compared to $11,529,000 at the end of the previous period[14]. - The company reported a significant increase in accounts payable by $6,141,000 during the nine months ended September 30, 2024[14]. Transformation and Strategy - Transformation-related benefits are now expected to reach $20 million, up from the previous estimate of $15 million[3]. - The company incurred a $8.1 million transformation charge and a $16.2 million charge related to the Dacthal product recall during the quarter[4]. - The company aims to decrease inventory to 34% of sales by year-end, representing a $25 million reduction compared to the previous year[4]. - The company is actively recruiting a CEO to continue its transformation momentum[3].

Financial Data and Key Metrics Changes - The company reiterated its 2024 adjusted EBITDA target of $40 million to $50 million and sales target of $565 million to $580 million, excluding product recall charges [7][28] - In Q3 2024, adjusted EBITDA was $2 million, down from $11 million in the same period last year, with sales of $130.7 million compared to $149.5 million [13][16] - Gross profit margin declined to 26% from 29% year-over-year, primarily due to decreased sales of Aztec [23] Business Line Data and Key Metrics Changes - U.S. crop business sales decreased by 30% or $20 million compared to Q3 2023, driven by significant declines in Aztec and Folex sales [16][18] - U.S. non-crop business saw a 17% increase in sales, led by a 45% increase in OHP distribution business [19] - Sales from the Green Solution product portfolio increased by 18% in Q3 and 20% year-to-date [20] Market Data and Key Metrics Changes - The international business experienced a 3% decline in sales, impacted by generic pressures and drought conditions in Australia [22] - The agricultural economy has shown signs of normalization after a downturn, with expectations for cautious inventory accumulation as the market moves into 2025 [10][11] Company Strategy and Development Direction - The company is focused on transforming into an efficient, reliable, and profitable supplier to the agricultural industry, with ongoing business transformation efforts expected to yield higher benefits than previously targeted [5][30] - A new customer-centric structure is being implemented to enhance decision-making and accountability across the organization [34][35] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about the cyclical recovery in the agricultural market, anticipating a strong fourth quarter driven by seasonal demand [12][38] - The company is addressing challenges from generics, particularly with Folex, by emphasizing service and superior product formulations [49][50] Other Important Information - The company reported a $16.2 million charge related to the voluntary recall of the Dacthal product line and an additional $8.1 million charge for transformation support [27] - Long-term debt was reduced by $32.5 million compared to the previous quarter, reflecting improved liquidity [25] Q&A Session Summary Question: Can you walk us through the levers for achieving the $50 million EBITDA guidance? - Management highlighted the seasonal strength of Q4 and the expected improvement in demand as key drivers for achieving the guidance [42] Question: What is the impact of generics on Folex and other products? - Management noted that Folex has been significantly impacted by generics, particularly in international markets, and emphasized the company's focus on service and product quality to compete [46][49] Question: Are there any additional costs expected from the Dacthal recall in Q4? - Management indicated that the current estimate of $16 million covers anticipated costs, but any new issues would be addressed as they arise [52]

Core Viewpoint - American Vanguard (AVD) reported a quarterly loss of $0.69 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.10, marking an earnings surprise of -590% [1] - The company's revenues for the quarter were $118.31 million, missing the Zacks Consensus Estimate by 14.52% and down from $149.52 million a year ago [2] Financial Performance - Over the last four quarters, American Vanguard has only surpassed consensus EPS estimates once [2] - The company has not beaten consensus revenue estimates in the last four quarters [2] - Year-to-date, American Vanguard shares have declined by approximately 47.4%, contrasting with the S&P 500's gain of 25.7% [3] Future Outlook - The company's earnings outlook will be crucial for investors, particularly in light of management's commentary during the earnings call [4] - Current consensus EPS estimate for the upcoming quarter is $0.13 on revenues of $169.1 million, while for the current fiscal year, the estimate is -$0.34 on revenues of $570.9 million [7] Industry Context - The Chemical - Specialty industry, to which American Vanguard belongs, is currently ranked in the bottom 36% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact American Vanguard's stock performance [5][6]

Core Viewpoint - An investigation is underway regarding potential breaches of fiduciary duties by the Board of Directors of American Vanguard Corporation (AVD) in light of significant health risks associated with its subsidiary AMVAC Chemical Corporation's pesticide DCPA [1][4]. Group 1: Investigation Details - Berger Montague is advising AVD shareholders about the investigation into the Board of Directors for potential breaches of fiduciary duties [1]. - The investigation focuses on the failure to ensure product safety and the exposure of the company to significant litigation risks [4]. Group 2: Regulatory Actions - In August 2024, the U.S. Environmental Protection Agency (EPA) suspended all registrations of the pesticide DCPA manufactured by AMVAC due to significant health risks to unborn babies [2]. - This suspension marks the first use of the EPA's emergency suspension powers in 40 years, highlighting the urgency of the health risks posed by DCPA [2]. Group 3: Historical Context - The EPA had previously alerted AMVAC to potential health risks related to DCPA in 2013, but the company failed to provide necessary data for over ten years [3]. - AMVAC only submitted the required test results in November 2023, which confirmed the significant risks posed to pregnant mothers and their unborn children [3].

Core Viewpoint - American Vanguard Corporation (AVD) reported a significant increase in losses for Q2 2024, with a loss of 42 cents per share compared to a loss of 4 cents per share in the same quarter last year. Adjusted loss was wider than expectations, and revenues fell short of estimates due to unfavorable market conditions [1]. Financial Performance - AVD's revenues for the quarter were $128.2 million, down approximately 3% year over year, missing the Zacks Consensus Estimate of $134.2 million [1]. - The U.S. crop business revenues decreased by roughly 7% year over year to about $52.3 million, while the U.S. non-crop business saw a 13% increase to around $19 million [2]. - International revenues declined by around 5% year over year to approximately $56.9 million, primarily due to lower herbicide sales [2]. - The company ended the quarter with cash and cash equivalents of roughly $17.9 million, a sequential increase of about 31%, while long-term debt rose to around $211.3 million, up approximately 13% sequentially [3]. Outlook - AVD has revised its full-year 2024 guidance for adjusted EBITDA down to $40-$50 million from a previous estimate of $60-$70 million. The company now anticipates net sales to be down 2% to flat, compared to an earlier forecast of 6-9% growth [4]. Price Performance - AVD's shares have experienced a significant decline of 62.8% over the past year, contrasting with a 13.9% decline in the industry [5].